Fehlings, M. http://orcid.org/0000-0002-0384-8408
Simoni, Y.
Penny, H. L.
Becht, E.
Loh, C. Y.
Gubin, M. M.
Ward, J. P.
Wong, S. C. http://orcid.org/0000-0003-3979-6096
Schreiber, R. D.
Newell, E. W. http://orcid.org/0000-0002-2889-243X
Article History
Received: 30 September 2016
Accepted: 16 July 2017
First Online: 15 September 2017
Change Date: 26 July 2018
Change Type: Correction
Change Details: The original version of this Article omitted a declaration from the competing interests statement, which should have included the following: ‘R.D.S. is a cofounder, stock holder, and scientific advisory board member of Jounce Therapeutics and Neon Therapeutics, and a member of the scientific advisory boards of BioLegend, Constellation, Lytix, and NGM. He also received research funding from Janssen and Agios.’. This has now been corrected in both the PDF and HTML versions of the Article.
Competing interests
: R.D.S. is a cofounder, stock holder and scientific advisory board member of Jounce Therapeutics and Neon Therapeutics, and a member of the scientific advisory boards of BioLegend, Constellation, Lytix and NGM. He also received research funding from Janssen and Agios. E.W.N. is a board director and shareholder of immunoSCAPE Pte. Ltd. M.F. is Director, Scientific Affairs and shareholder of immunoSCAPE Pte. Ltd. All other authors declare no competing financial interests.